Hikma Pharmaceuticals (LON:HIK) Receives “Neutral” Rating from Citigroup
Other equities analysts also recently issued research reports about the stock. Peel Hunt reaffirmed a hold rating on shares of Hikma Pharmaceuticals in a research note on Monday, February 24th. Jefferies Financial Group cut their price target on shares of Hikma Pharmaceuticals from GBX 2,310 ($30.39) to GBX 2,240 ($29.47) and set a buy rating on the stock in a research note on Tuesday, January 21st. HSBC reaffirmed a reduce rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, November 27th. JPMorgan Chase & Co. increased their price target on shares of Hikma Pharmaceuticals from GBX 1,800 ($23.68) to GBX 1,850 ($24.34) and gave the stock a neutral rating in a research note on Monday, January 6th. Finally, Barclays reaffirmed an equal weight rating on shares of Hikma Pharmaceuticals in a research note on Thursday, February 20th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the stock. Hikma Pharmaceuticals currently has an average rating of Hold and a consensus price target of GBX 1,853.33 ($24.38).
LON:HIK traded down GBX 122 ($1.60) during trading hours on Friday, reaching GBX 1,788 ($23.52). 1,097,163 shares of the company were exchanged, compared to its average volume of 822,138. The company has a debt-to-equity ratio of 37.69, a current ratio of 1.28 and a quick ratio of 0.78. The firm has a market cap of $4.33 billion and a price-to-earnings ratio of 12.02. Hikma Pharmaceuticals has a 52-week low of GBX 16.58 ($0.22) and a 52-week high of GBX 2,089.19 ($27.48). The stock has a 50 day simple moving average of GBX 1,902.26 and a 200 day simple moving average of GBX 1,964.34.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals.
Recommended Story: Bid-Ask Spread
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.